



**ASX & MEDIA RELEASE**

**1 August 2016**

**MEDLAB SUPPORTS NSW GOVT LEGALISING PRESCRIPTION OF CANNABIS AS IT PREPARES FOR HUMAN TRIALS WITH CANNABIS**

Nutritional pharmaceutical company, Medlab Clinical Limited (ASX: MDC), supports the New South Wales government decision to allow doctors to legally prescribe cannabis for patients.

This new regime begins today, 1 August, and will remove the problem of patients obtaining cannabis illegally.

Medlab also supports comments from NSW Medical Research Minister, the Hon Pru Goward, who notes there is still a lot to learn about the safety and efficacy of cannabis for patient conditions.

Medlab notes the effect of the new regime is to legalise use of cannabis based medicines, not the supply of cannabis, for which approval from the Therapeutic Goods Administration is required for cannabis to be used for medical purposes.

Medlab is preparing to commence human trials of a cannabis based medicine, involving a therapeutic combination of two cannabis compounds, CBD (cannabidiol) and THC (tetrahydrocannabinol) for pain using a small particle mouth spray, adopting Medlab's NanoCelle™ technology.

Medlab's combination of these compounds is based on its research which shows that both CBD and THC are required for effective treatment in pain management therapies.

Medlab's Managing Director, Mr Sean Hall, said the state governments move was welcomed in highlighting the benefits of cannabis as a pain management tool.

"It also supports the more scientific pursuit of clinically tested medicines which are the outcome of the research Medlab is pursuing," Mr Hall said

Medlab is currently completing a capital raising of \$5.4 million to accelerate its cannabis trial and further development of NanoCelle™.

In April this year, Medlab won a category of the 2016 Biotechnology Awards from UK based *Global Health & Pharma* for Best Early-Phase Chronic Disease Drug Discovery Company.

---

**ISSUED FOR:** MEDLAB CLINICAL LTD (ASX: MDC) – [www.medlab.co](http://www.medlab.co)

**FOR FURTHER INFORMATION:** MR SEAN HALL, CEO, MEDLAB CLINICAL  
TEL: +61 2 8203 9520, [sean\\_hall@medlab.co](mailto:sean_hall@medlab.co)

**ISSUED BY:** HILL + KNOWLTON STRATEGIES, MARCHA VAN DEN HEUVEL  
TEL +61 2 9286 1226 OR +61 468 960 457, [marcha.vandenheuvel@hkstrategies.com](mailto:marcha.vandenheuvel@hkstrategies.com)

**ABOUT MEDLAB – [www.medlab.co](http://www.medlab.co)**

Medlab Clinical is an Australian based biotechnology company, with a certified biologics facility in Sydney and sales arms in Australia and California (Medlab Clinical US LTD, formerly InMed Technologies). The research focus is on the role bacteria in the gastrointestinal tract play in health and disease, in five health areas: obesity, chronic kidney disease, depression, ageing and muscular skeletal health and pain management. Medlab develops and sells nutraceuticals in the US and Australia to support drug discovery and development of new medicines involving bacteria (pharmacobiotics). Medlab currently has an impressive patent portfolio, multiple published research papers and conference presentations and the Pharmacobiotic trademark – a therapeutic term referring to both probiotics and biologics.

Medlab Clinical Limited, 66 McCauley St, Alexandria NSW 2015

P: +61 2 8188 0311 F: +61 2 9699 3347 W: [www.medlab.co](http://www.medlab.co)